Emerging therapeutic avenues in cardiac amyloidosis

Golatkar, Vaishnavi; Bhatt, Lokesh Kumar

doi:10.1016/j.ejphar.2023.176142

Cited by 2 publications

(1 citation statement)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we found a large number of positive SOC signals and positive AE signals associated with primary diseases, such as cardiac disorders and cardiac amyloidosis. When the TTR protein misfolds, it can form amyloid fibrils that deposit in the heart causing heart failure, heart conduction block, or arrhythmia such as atrial fibrillation 1,17,18 . The large number of positive AE signals such as cardiac failure, atrial fibrillation, and cardiomyopathy that were found in this study are consistent with the disease presentation of ATTRamyloidosis.…”

Section: Discussionmentioning

confidence: 99%

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

Wu,

Zhu,

Zhang

2024

Sci Rep

View full text Add to dashboard Cite

Tafamidis is the world's first and only oral drug approved to treat the rare disease transthyretin amyloid cardiomyopathy (ATTR-CM). Medicines are known to have different adverse reactions during the course of treatment. However, the current limited clinical studies did not identify significant adverse drug reactions to tafamidis. Tafamidis has been on the market for 5 years now, a large number of adverse drug event (ADE) reports with tafamidis as the primary suspected drug have been reported in the United Food and Drug Administration's adverse event reporting system (FAERS). We retrieved 8170 adverse event reports in FAERS with tafamidis as the first suspected drug, and mined these reports for positive signals to perform risk warnings for potentially possible adverse events with tafamidis. We found that a large number of adverse events associated with the primary disease were reported due to insufficient awareness of ATTR among the reporters, leading to a large number of positive signals reported in the cardiac disorders system. We also found that tafamidis has the potential to cause an adverse event risks of ear and labyrinth disorders system and urinary tract infection bacterial, which deserve continued clinical attention.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

Wu,

Zhu,

Zhang

2024

Sci Rep

View full text Add to dashboard Cite

show abstract

Histopathological and Immunohistochemical Characteristics of Different Types of Cardiac Amyloidosis

Gioeva,

Mikhaleva,

Gutyrchik

et al. 2024

IJMS

View full text Add to dashboard Cite

Cardiac involvement is the most important factor determining prognosis in patients with systemic amyloidosis. This retrospective observational study of 98 patients with amyloidosis was undertaken to assess the amyloid types that are most likely to affect the heart, describe histopathological and clinical features of cardiac amyloidosis, and estimate the number of cases not diagnosed clinically prior to death. All cases were divided into two groups based on the method of examination. The first group included 46 patients with cardiac amyloidosis revealed via endomyocardial biopsies (EMBs), and the second group included 52 amyloidosis patients who did not undergo EMBs, in whom cardiac involvement was identified only at autopsy. The EMBs demonstrated that AL amyloidosis was detected in 21 (46%) specimens, ATTR amyloid in 24 cases (52%), and AA amyloid in 1 case (2%). The autopsy reports defined 15 (46%) cases of AL amyloidosis, 21 (40%) of ATTR and 16 (31%) of AA amyloidosis. It should be noted that a clinical diagnosis of ATTR amyloidosis was made only in 9.5% of patients from the autopsy group, suggesting that ATTR may be an underdiagnosed cause of heart failure in elderly patients. The most intense amyloid deposits were determined in biopsy and autopsy specimens of patients with AL kappa amyloidosis, underlying a poorer prognosis.

show abstract

Emerging therapeutic avenues in cardiac amyloidosis

Cited by 2 publications

References 92 publications

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

Histopathological and Immunohistochemical Characteristics of Different Types of Cardiac Amyloidosis

Contact Info

Product

Resources

About